Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors

Journal of Pain and Symptom Management

Volumn 52, Issue 2, 2016, Pages 265-271

  Poort, Hanneke ^a   van der Graaf, Winette T A ^a,b   Tielen, Ronald ^a   Vlenterie, Myrella ^a   Custers, José A E ^a   Prins, Judith B ^a   Verhagen, Constans A H H V M ^a   Gielissen, Marieke F M ^a,c   Knoop, Hans ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fatigue; gastrointestinal stromal tumors; molecular targeted therapy; quality of life

Indexed keywords

IMATINIB; NILOTINIB; SUNITINIB; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ASSESSMENT OF HUMANS; CANCER PALLIATIVE THERAPY; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DISTRESS SYNDROME; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FATIGUE CATASTROPHIZING SCALE; FATIGUE SEVERITY SCALE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUALITY OF LIFE; SELF EFFICACY SCALE; SHORT FORM 36; SOCIAL PSYCHOLOGY; GASTROINTESTINAL TUMOR; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84983071801     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2016.02.019     Document Type: Conference Paper

References (28)

1. 1 DeMatteo, R.P., Lewis, J.J., Leung, D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000), 51–58.
2. 2 Dematteo, R.P., Heinrich, M.C., El-Rifai, W.M., Demetri, G., Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002), 466–477.
3. 3 Blanke, C.D., Demetri, G.D., von Mehren, M., et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008), 620–625.
4. 4 Hofman, M., Ryan, J.L., Figueroa-Moseley, C.D., Jean-Pierre, P., Morrow, G.R., Cancer-related fatigue: the scale of the problem. Oncologist 12 (2007), 4–10.
5. 5 Dematteo, R.P., Ballman, K.V., Antonescu, C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (2009), 1097–1104.
6. 6 Sodergren, S.C., White, A., Efficace, F., et al. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 91 (2014), 35–46.
7. 7 National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology for adverse events version 3.0 (CTCAE). Available at: http://ctep.cancer.gov. Accessed November 17, 2015.
8. 8 Basch, E., Jia, X., Heller, G., et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101 (2009), 1624–1632.
9. 9 Goedendorp, M.M., Gielissen, M.F., Verhagen, C.A., Bleijenberg, G., Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J Pain Symptom Manage 45 (2013), 213–222.
10. 10 Peters, M.E., Goedendorp, M.M., Verhagen, S.A., van der Graaf, W.T., Bleijenberg, G., Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psychooncology 23 (2014), 773–779.
11. 11 Prue, G., Allen, J., Gracey, J., Rankin, J., Cramp, F., Fatigue in gynecological cancer patients during and after anticancer treatment. J Pain Symptom Manage 39 (2010), 197–210.
12. 12 CentERdata. About CentERdata. Available at: http://www.centerdata.nl/. Accessed November 17, 2015.
13. 13 Vercoulen, J.H., Swanink, C.M., Fennis, J.F., et al. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 38 (1994), 383–392.
14. 14 Gielissen, M.F., Verhagen, S., Witjes, F., Bleijenberg, G., Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 24 (2006), 4882–4887.
15. 15 Goedendorp, M.M., Peters, M.E., Gielissen, M.F., et al. Is increasing physical activity necessary to diminish fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial. Oncologist 15 (2010), 1122–1132.
16. 16 Aaronson, N.K., Ahmedzai, S., Bergman, B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
17. 17 Gielissen, M.F., Verhagen, C.A., Bleijenberg, G., Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer 97 (2007), 612–618.
18. 18 Broeckel, J.A., Jacobsen, P.B., Horton, J., Balducci, L., Lyman, G.H., Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16 (1998), 1689–1696.
19. 19 Vodermaier, A., Millman, R.D., Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer 19 (2011), 1899–1908.
20. 20 van der Zee, K.I., Sanderman, R., Measuring general health status with the RAND-36: a manual. 2nd ed., 2012, UMCG/Rijksuniversiteit Groningen, Research Institute SHARE, Groningen.
21. 21 Mock, V., Atkinson, A., Barsevick, A., et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14 (2000), 151–161.
22. 22 Bennett, B., Goldstein, D., Lloyd, A., Davenport, T., Hickie, I., Fatigue and psychological distress: exploring the relationship in women treated for breast cancer. Eur J Cancer 40 (2004), 1689–1695.
23. 23 Hjermstad, M.J., Oldervoll, L., Fossa, S.D., et al. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 42 (2006), 327–333.
24. 24 Prue, G., Rankin, J., Allen, J., Gracey, J., Cramp, F., Cancer-related fatigue: a critical appraisal. Eur J Cancer 42 (2006), 846–863.
25. 25 Servaes, P., Verhagen, C., Bleijenberg, G., Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 38 (2002), 27–43.
26. 26 Mock, V., Pickett, M., Ropka, M.E., et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 9 (2001), 119–127.
27. 27 Cramp, F., Byron-Daniel, J., Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev, 2012, CD006145.
28. 28 Custers, J.A., Tielen, R., Prins, J.B., et al. Fear of progression in patients with gastrointestinal stromal tumors (GIST): is extended lifetime related to the Sword of Damocles?. Acta Oncol 54 (2015), 1201–1208.